Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Natriuretic peptide receptor A (NPR-A) is a transmembrane receptor that primarily binds atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP). It is a key mediator of the physiological effects of these hormones, which include regulation of blood pressure, blood volume, and cardiovascular homeostasis. Binding of ANP or BNP to the extracellular domain induces conformational changes leading to dimerization and activation. This triggers conversion of GTP to cGMP by the guanylyl cyclase activity in the intracellular domain. Increased cGMP activates downstream effectors such as cGMP-dependent protein kinase G (PKG), leading to vasodilation, diuresis, natriuresis, and inhibition of cell proliferation/apoptosis/inflammation.
Activation of guanylyl cyclase, leading to increased cGMP production and downstream signaling via PKG.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Type A Natriuretic Peptide Receptor (NPR-A).